Vanda Pharmaceuticals (VNDA) will pay Eli Lilly (LLY) up to $100M for exclusive rights to develop a drug that has shown promise as a treatment for alcohol addiction. The company calls the licensing of VLY-686 "an important milestone for Vanda, as we continue to realize our vision of developing treatments to address unmet medical needs."
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs